DIAFEVER algorithm
Diagnostic TestPCT rapid test-based predictive algorithm
NCT Number: NCT03607162
Because a newly available point-of-care test may have real interest especially for children in the Emergency Department (ED) setting, by limiting painful and stressful venipunctures and decreasing the length of stay in the ED, the investigators hypothesize that integrating this new capillary Procalcitonin (PCT) rapid test in the DIAFEVER CPR (Clinical Prediction Rules) could represent a highly valuable diagnostic tool to identify a group with low Invasive Bacterial Infection (IBI) risk and could limit unnecessary exams and antibiotic prescriptions. The aim of this present study is to demonstrate the impact of this new PCT rapid-test-based CPR on antibiotic prescription rate in young children with Fever Without Source (FWS) presenting to the ED and on morbidity and mortality
Looking for future studies?
Notify Me6 day–36 month
All sexes
Interventional
Not applicable
University Hospital, Angers, France
This prospective multicentric randomized study will include 5000 febrile children aged six days to three years, diagnosed with fever without source, in 26 participating French and Swiss emergency departments, during a 36-month period.
During one period, all children will receive usual care. In a second period, the DIAFEVER algorithm will be applied in half of the clusters, and in the remaining clusters, children will still receive usual care.
Then in the last period of one year, all centers will apply the new PCT-based algorithm.
At day 15 after the first consultation, data concerning death, intensive care unit admission, disease-specific complications, diagnosis of bacterial infections and proportion of antibiotic treatments will be assessed by questioning parents by use of an online electronic case report form or a phone call. The endpoints will be compared between the two groups by using a mixed logistic regression model adjusted on clustering of participants within centers and period within centers.
To perform complementary studies, a biocollection will be proposed to parents when blood tests will be indicated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PCT rapid test-based predictive algorithm
Time frame: at day 15 after the first ED consultation
Related to the superiority objective : change in antibiotics exposure based on the proportion of children who received ABT
Time frame: At inclusion visit
The incidence of FWS among children admitted in EDs, the incidence of Severe Bacterial Infection (SBI) and IBI among the children admitted in the ED with FWS
Time frame: At inclusion visit
Assessment of sensitivity, specificity, predictive values, Likelihood Ratio, of the DIAFEVER prediction rule (combining high- and intermediate-risk versus low-risk populations) considering the SBI/IBI diagnosis as the gold standard
Time frame: at day 15 after the first ED consultation
Time frame: at day 15 after the first ED consultation
Time frame: at day 15 after the first ED consultation
Time frame: at day 15 after the first ED consultation
Time frame: at day 15 after the first ED consultation
theoretically vaccine-preventable SBI is defined as an infection with an identified serotype included in the national vaccine schedule and occurring in a child with untimely vaccination
Time frame: at day 15 after the first ED consultation
Morbidity and mortality based on a binary composite outcome considering occurrence or not during the 15 days after discharge from the ED of one of the following events:
Nantes University Hospital
Other
Impact of a New Sequential Approach on Antimicrobial Use in Young Children With Fever Without Source in Emergency Department
Acronym: DIAFEVER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00692848
Bacteremia, Bacterial Infection
Montreal, Quebec, Canada
View Trial DetailsNCT02025699
Bacteremia, Bacterial Infections
Hadera, Israel
View Trial DetailsNCT01917461
Digestive System Diseases, Fever Without Source
Hadera, Israel
View Trial DetailsNCT02179398
Fever Without Source
Geneva, Geneva 14, Switzerland
View Trial Details